Research Analysts’ Recent Ratings Changes for Cingulate (CING)

A number of research firms have changed their ratings and price targets for Cingulate (NASDAQ: CING):

• 8/29/2026 – Cingulate was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/23/2026 – Cingulate was given a new $9.00 price target by Roth Capital. They now have a “buy” rating on the stock.
• 8/18/2026 – Cingulate was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/15/2026 – Cingulate was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/24/2026 – Cingulate was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/9/2026 – Cingulate was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.